Significance Statement {#s5}
======================

The efficacy of fronto-temporal transcranial direct current stimulation (tDCS) in treating auditory verbal hallucinations (AVHs) and other psychopathological symptoms of schizophrenia patients has been examined in a small number of clinical trials with limited sample sizes. Fronto-temporal tDCS has also been demonstrated to enhance patients' insight into their mental illness in an open-label pilot study. We hypothesized that fronto-temporal tDCS may not only improve AVHs and other psychotic symptoms but also intensify insight in schizophrenia. Our main findings indicated that tDCS did not reduce AVHs and other psychopathological symptoms. After treatment with tDCS, however, patients' insight into illness and positive symptoms rapidly heightened. The beneficial effect of tDCS on insight lasted for at least 1 month. These observations suggest that fronto-temporal tDCS is not effective for AVHs and other schizophrenia symptoms, but its effect on insight levels provides a new direction for future research into insight promotion interventions in schizophrenia.

Introduction {#s6}
============

A large proportion of patients with schizophrenia experience auditory verbal hallucinations (AVHs), one of the core symptoms of schizophrenia ([@CIT0052]). Antipsychotic medication is currently the mainstay of treatment for AVHs. However, nearly 30% patients with AVHs are nonresponsive to traditional antipsychotics ([@CIT0046]), and these patients do not always agree with or tolerate treatment with adequate doses of clozapine or electroconvulsive therapy to treat their medication-refractory AVHs. Researchers keep trying to develop well-tolerated alternative or add-on therapies to treat medication-refractory AVHs in schizophrenia patients. Transcranial direct current stimulation (tDCS) is one of the add-on neurostimulation therapies that has raised great interest in recent years. This noninvasive technique applies a weak direct current on the scalp and through the brain and rapidly leads to changes in cortical excitability by shifting membrane resting potentials, which facilitates either depolarization or hyperpolarization of the brain neurons ([@CIT0035]). Repetitive stimulation during specific time intervals further enhances efficacy and prolongs after-effects of tDCS by modifying the efficacy of N-methyl-D-aspartate receptor ([@CIT0036]).

Functional neuroanatomical studies have described a common observation of hypoactivity in the prefrontal cortex among patients with schizophrenia ([@CIT0028]) and during their AVHs, the observations of hyperactivity in the left temporo-parietal brain areas ([@CIT0025]) and a fronto-temporal functional dysconnectivity ([@CIT0002]). A pilot trial based on the prior observations has examined the potential treatment effects of fronto-temporal tDCS (twice daily stimulation for total 10 sessions, with the anode placed over the left prefrontal cortex and the cathode over the left temporo-parietal junction) for treating medication-refractory AVHs in schizophrenia and the results are very promising, giving hope for future clinical application ([@CIT0009]). Some studies that successfully replicated the original pilot study have further confirmed a therapeutic benefit of tDCS, manifested by reductions in frequency and/or severity of AVHs in schizophrenic patients ([@CIT0033], [@CIT0034]; [@CIT0008]). However, other studies that applied the stimulation once daily for 15 ([@CIT0017]) or 5 sessions ([@CIT0048]; [@CIT0018]) failed to replicate previous positive findings. A recent systematic review analyzed all these clinical trials with limited sample sizes (numbers ranging from 23 to 33) and pointed out that the information is incongruent and insufficient for determining the clinical use of tDCS to reduce the severity of AVHs in schizophrenia ([@CIT0039]). A large randomized controlled trial with higher statistical power is necessary to draw a firm conclusion.

Lack of insight into illness is common in patients with schizophrenia and has a negative impact on treatment adherence, long-term illness outcome, and prognosis ([@CIT0029]). Insight in schizophrenia interacts with psychopathology symptoms in a complex way. For example, poor insight seems to be particularly associated with increased severity of positive symptoms ([@CIT0050]; [@CIT0054]). The presence of reduced insight has been considered a state characteristic that might contribute to the phenomenology of AVHs, for example, determining the meaning of AVHs ([@CIT0053]). Therapeutic interventions do improve insight in schizophrenia ([@CIT0038]), but 50% to 80% of schizophrenia patients have impaired insight into the presence of their mental disorder and therefore poorly comply with the recommended treatment ([@CIT0029]). Researchers have been seeking specific brain regions implicated in impaired insight in schizophrenia and for interventions to promote insight among patients with schizophrenia. A recent open-label study stands on the premise that structural and functional brain deficits in prefrontal ([@CIT0042]; [@CIT0011]) and temporo-parietal cortical regions ([@CIT0010]; [@CIT0016]) is highly correlated with poor insight in schizophrenia as reported in earlier studies and successfully demonstrated the insight facilitation effects of add-on fronto-temporal tDCS in schizophrenia ([@CIT0007]). The positive effect needs to be confirmed in randomized controlled trials with adequate statistical power.

The present study aimed to examine the acute effect of 5 consecutive days of fronto-temporal tDCS and its maintenance effects at 1 month and 3 months follow-up on refractory AVHs in schizophrenia patients. We anticipated that fronto-temporal tDCS attenuates the severity of AVHs in schizophrenia. We also assessed the effects of fronto-temporal tDCS on other psychopathological symptoms and the levels of insight across the same study period.

Methods {#s7}
=======

Participants {#s8}
------------

Patients who met DSM-IV-TR criteria for schizophrenia or schizoaffective disorder were enrolled in the study. None of them had any current psychiatric comorbidity or active substance use disorder. All participants aged 20 to 65 years were provided written informed consent for the study as approved by the Institutional Review Board of Tri-Service General Hospital (no. of IRB approval: TSGHIRB-2-103-03-002; ClinicalTrials.gov ID: NCT03388554). All participants had medication-refractory auditory verbal hallucinations, which are defined as the persistence of daily hallucinations without remission under adequate treatments with antipsychotic medications at clinical efficacious tolerated dose for more than 3 months. Throughout the duration of the study, their antipsychotic treatment was unchanged. The daily dosage of antipsychotic drugs equivalent to 100 mg chlorpromazine was calculated. A randomized, double-blind, parallel arm, stimulation protocol was used in our study. An Eldith DC stimulator (Neuroconn DC Stimulator Plus, GmbH, Ilmenau, Germany) was used for stimulation, with two 7×5 cm sponge electrodes soaked in a 0.9% NaCl saline solution. In line with previous studies and based on the international 10 to 20 electrode placement system, the middle of the anode was located over a point midway between F3 and FP1, presumably corresponding to left prefrontal cortex and dorsolateral prefrontal cortex. The cathode was centered at a point midway between T3 and P3, corresponding to left temporo-parietal junction. Stimulation was applied at an intensity of 2 mA for 20 minutes, twice daily, on 5 consecutive weekdays. In sham stimulation, the 2-mA current was turned on for 30 seconds and then ramped down to 0 mA through the remainder of the 20-minute time.

Outcome Measurement {#s9}
-------------------

The primary outcome measure was the variation during the study period in score of the Auditory Hallucination Rating Scale (AHRS), which is used to assess multiple characteristics of AVHs and thereby quantify the severity of AVHs ([@CIT0024]). Secondary outcome measures comprised the changes over time in the severity of other schizophrenia symptoms and the level of patient insight. Other schizophrenia symptoms were measured by the Positive and Negative Syndrome Scale (PANSS) and 5 main symptom dimensions of PANSS: positive, negative, grandiosity/excitement, disorganization, and depression ([@CIT0031]). The level of patient insight was assessed by using the abbreviated version of the Scale to Assess Unawareness in Mental Disorder in schizophrenia (SUMD), which is an expert-rating scale based on a patient interview ([@CIT0032]). The abbreviated version of SUMD comprises 9 items measuring current states of awareness as follows: (1) a mental disorder, (2) consequences of a mental disorder, (3) effects of drugs, (4) hallucinatory experiences, (5) delusional ideas, (6) disorganized thoughts, (7) blunted affect, (8) anhedonia, and (9) lack of sociability. Scores on each item range from 0 to 3. A score of 0 indicates not applicable; 1, aware; 2, somewhat aware/unaware; and 3, severely unaware. Based on the 3-dimensions approach of the abbreviated version of SUMD, the scores on the items 1 to 3, 4 to 6, and 7 to 9 were averaged to obtain the dimension score of awareness of the disease, awareness of positive symptoms, and awareness of negative symptoms, respectively. All dimension scores were linearized on a 0 to 100 scale, with 0 and 100 indicating the lowest and highest level of unawareness, respectively. A rater (H.A.C.) who was blinded to the group assignment administered the AHRS, PANSS, and the abbreviated version of SUMD at baseline, immediately after the 5 days of tDCS and 1 and 3 months after tDCS. All participants were reimbursed for their transportation costs and time spent at each appointment attended.

Statistical Analyses {#s10}
--------------------

IBM SPSS Statistics 21.0 software (IBM SPSS Inc., Chicago, IL) was used for analyses. For the comparisons of continuous variables between the 2 groups, Student's *t* tests were used for parametric variables and the Mann-Whitney tests for nonparametric variables. The χ2 and Fisher's tests were used to examine between-group differences in discrete variables. To compare the effects of tDCS on primary and secondary outcomes over time in the 2 groups, a repeated-measures ANOVA (RMANOVA) was used to analyze the data from the full intent-to-treat sample, with time as the within-group factor and treatment as the between-group factor. RMANCOVA analysis was used to control for baseline significant differences that might have potential confounding effects. When a significant treatment group-by-time interaction effect was found, posthoc analyses were performed by using Student's *t* tests for between-group comparisons. All results are 2-tailed, statistical significance was defined as *P\<*.05, and Bonferroni adjustment was used to correct for multiple tests in which only *P\<*.005 (0.05/10) were considered significant. For the percent changes in primary and secondary outcomes before and after 5 days of tDCS sessions, between-groups comparisons were undertaken and Cohen's d effect sizes were calculated by using G\*power Version 3.1.9.2. Cohen's guidelines ([@CIT0013], [@CIT0014]) identify 0.2, 0.5, and 0.8 as small, medium, and large effects, respectively. Power analysis was performed with the use of G\*power Version 3.1.9.2.

Results {#s11}
=======

Sample Characteristics {#s12}
----------------------

The CONSORT flow chart was shown in [Figure 1](#F1){ref-type="fig"}. Sixty patients, all right-handed, were included in our study. Fifty-one of them had a diagnosis of schizophrenia and 9 had a diagnosis of schizoaffective disorder. Thirty patients were randomly assigned to the active tDCS group and 30 to the sham group. There was no significant between-group difference in demographic data. Patients in the active tDCS group had longer illness duration, a higher depression score of PANSS, and a higher domain score in awareness of negative symptoms of the abbreviated SUMD ([Table 1](#T1){ref-type="table"}).

![Flow diagram of the participant progress through the phases of the present randomized trial.](pyy07401){#F1}

###### 

Baseline Demographic and Clinical Characteristics of the Participants

  Characteristics                                                    Active tDCS            Sham tDCS              t/U or χ2/Fisher's   *P* value
  ------------------------------------------------------------------ ---------------------- ---------------------- -------------------- -----------
  Number of participants                                             30                     30                                          
  Females (%)                                                        16 (53.30)             17 (56.70)             0.07                 .80
  Age, mean±SD (range), years                                        46.40±10.29 (22--65)   42.17±10.29 (23--60)   1.46                 .15
  Education level, mean±SD, years                                    13.17±2.57             13.03±2.53             0.20                 .84
  BMI, mean±SD, kg/m^2^                                              25.77±3.75             25.29±4.86             0.43                 .67
  Smokers (%)                                                        10 (33.33)             4 (13.30)              3.35                 .13
  Onset age, mean±SD, years                                          26.50±8.88             28.27±9.85             -0.73                .47
  Length of illness, mean±SD, years                                  19.73±10.36            13.90±7.50             2.50                 .02
  Antipsychotic dosage, mean±SD, mg/d (chlorpromazine equivalents)   493.81±306.76          493.32±284.93          0.01                 1.00
  AHRS score, mean±SD                                                29.13±5.31             29.07±4.83             0.05                 .96
  Positive and Negative Syndrome Scale                                                                                                  
  Total score, mean±SD                                               72.33±13.19            66.73±12.49            1.69                 .10
  Positive score, mean±SD                                            13.53±4.64             12.97±3.41             0.54                 .59
  Negative score, mean±SD                                            22.83±4.98             21.40±4.67             1.15                 .26
  Grandiosity/excitement score, mean±SD                              5.73±2.27              5.30±1.73              0.83                 .41
  Disorganization score, mean±SD                                     11.43±2.30             10.60±2.31             1.40                 .17
  Depression score, mean±SD                                          6.43±1.99              5.43±1.72              2.08                 .04
  The abbreviated version of the SUMD                                                                                                   
  Awareness of disease, mean±SD                                      90.00±13.79            84.07±15.90            363.00               .16
  Awareness of positive symptoms, mean±SD                            62.59±19.89            55.93±15.30            363.50               .18
  Awareness of negative symptoms, mean±SD                            86.67±16.09            75.19±15.35            290.50               .009

Abbreviations: AHRS, Auditory Hallucination Rating Scale; BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); SUMD, Scale to Assess Unawareness in Mental Disorder.

Statistical Power {#s13}
-----------------

The present total sample had a power of 0.966 to detect a small effect (Cohen's d=0.2) for the primary and secondary outcomes.

Primary Outcome {#s14}
---------------

In the active tDCS group, AHRS score was decreased 7.95±11.73% immediately after tDCS, 5.86±7.43% at 1 month, and 4.52±7.17% at 3 months ([Figure 1](#F1){ref-type="fig"}). In the sham group, AHRS score was decreased 3.81±4.98% immediately after tDCS, 4.34±5.71% at 1 month, and 5.03±6.11% at 3 months. The RMANOVA for AHRS score showed no significant interaction between group and time \[F(3,56)=2.59, *P=*.062\]. The negative result remained after controlling for confounding effects of illness duration, baseline depression, and awareness of negative symptoms by covarying them in RMANCOVA \[F(3,53)=1.56, *P=*.211\]. As seen in [Table 2](#T2){ref-type="table"}, the acute effect of 5 days of tDCS on auditory verbal hallucination (from 29.13±5.31 to 26.73±5.64) showed a small effect size compared with the sham group (from 29.07±4.83 to 27.97±4.91), but the effect did not reach statistical significance.

###### 

Percent Decrease in the Severity of Auditory Verbal Hallucinations and Other Schizophrenia Symptoms and Levels of Impaired Insight after 5 Days of tDCS or Sham Treatment in the Participants

  --------------------------------------------------------------------------------------------------------------------------
  Outcome measures                            Active tDCS\   Sham tDCS\     F       *P* value   Partial η^2^   Effect size
                                              (n=30)\        (n=30)\                                           
                                              Mean±SE^*a*^   Mean±SE^*a*^                                      
  ------------------------------------------- -------------- -------------- ------- ----------- -------------- -------------
  Auditory Hallucination Rating Scale score   7.83±1.79      3.94±1.79      2.11    .15         0.037          0.196

  Positive and Negative Syndrome Scale                                                                         

  Total score                                 2.88±0.66      0.81±0.66      4.37    .041        0.074          0.283

  Positive score                              4.05±1.10      1.83±1.10      1.81    .18         0.032          0.182

  Negative score                              1.24±0.90      0.38±0.90      0.40    .53         0.007          0.084

  Grandiosity/excitement score                -4.42±2.31     -0.07±2.31     1.57    .21         0.028          0.170

  Disorganization score                       0.87±0.57      0.07±0.57      0.89    .35         0.016          0.128

  Depression score                            2.29±1.06      1.16±1.06      0.51    .48         0.009          0.095

  The abbreviated version of the SUMD                                                                          

  Awareness of disease                        31.49±3.80     9.92±3.80      14.34   \<.001      0.207          0.511

  Awareness of positive symptoms              36.57±3.91     2.58±3.91      33.54   \<.001      0.379          0.781

  Awareness of negative symptoms              13.77±2.72     0.43±2.72      10.71   .002        0.163          0.441
  --------------------------------------------------------------------------------------------------------------------------

Abbreviations: SUMD, Scale to Assess Unawareness in Mental Disorder; tDCS, Transcranial Direct Current Stimulation.

^*a*^Values were adjusted for covariates (illness duration, baseline depression, and awareness of negative symptoms).

Secondary Outcomes {#s15}
------------------

The RMANOVA showed no significant group-by-time interaction for total PANSS score \[F(3,56)=4.35, *P=*.008\] and for the scores of symptoms dimensions of positive \[F(3,56)=1.63, *P=*.19\], negative \[F(3,56)=1.84, *P=*.15\], grandiosity/excitement \[F(3,56)=0.24, *P=*.87\], disorganization \[F(3,56)=2.42, *P=*.08\], or depression \[F(3,56)=2.09, *P=*.11\].These negative results were unchanged after controlling for confounding effects. The acute effects of tDCS on total PANSS score and the scores of symptoms dimensions showed small or even trivial effects compared with the sham group, and the effects were not statistically significant ([Table 2](#T2){ref-type="table"}).

There were significant group-by-time interaction effects for the SUMD dimension scores of awareness of the disease \[F(3,56)=7.97, *P\<*.001\], awareness of positive symptoms \[F(3,56)=13.27, *P\<*.001\], and awareness of negative symptoms \[F(3,56)=6.13, *P=*.001\]. The results remained unchanged after adjusting for the covariates of illness duration and baseline depression in the RMANCOVA model. Additional correction for the potential confounder of awareness of negative symptoms did not change significant group-by-time interaction for the SUMD dimension scores of awareness of the disease \[F(3,53)=6.06, *P=*.001\] and awareness of positive symptoms \[F(3,53)=9.89, *P\<*.001\] but reduced the interaction for awareness of negative symptoms to nonsignificant \[F(3,53)=4.48, *P=*.007\]. Posthoc analyses showed that the significant interaction effects for the SUMD dimension scores of awareness of the disease and awareness of positive symptoms were mainly due to the acute effect of 5 days of active tDCS to reduce the 2-dimension scores, with moderate effect sizes compared with sham treatment ([Table 2](#T2){ref-type="table"}). However, the maintenance effects (from end of treatment to 3 months) of tDCS on awareness of the disease ([Figure 3](#F3){ref-type="fig"}) and awareness of positive symptoms ([Figure 4](#F4){ref-type="fig"}) faded with time. Between-group differences in percent decrease of the 2 SUMD dimension scores were significant after tDCS and at 1 month but were no longer significant at 3 months.

![The mean percentage changes in scores of Auditory hallucination Rating Scale (AHRS) between active stimulation group and sham group across the 4 assessments. Error bars indicated the SE. Posthoc analyses were undertaken to examine between-group difference at each post-baseline assessment with *P* \<.005 (0.05/10) considered significant. \**P\<*.005; \*\**P\<*.001.](pyy07402){#F2}

![The mean percentage changes in the awareness of the disease dimension scores of the abbreviated version of the Scale to Assess Unawareness in Mental Disorder in schizophrenia (SUMD) between active stimulation group and sham group across the 4 assessments. Other descriptions are as in [Figure 2](#F2){ref-type="fig"}.](pyy07403){#F3}

![The mean percentage changes in the awareness of positive symptoms dimension scores of the abbreviated version of the Scale to Assess Unawareness in Mental Disorder in schizophrenia (SUMD) between active stimulation group and sham group across the 4 assessments. Other descriptions are as in [Figure 2](#F2){ref-type="fig"}.](pyy07404){#F4}

Side Effects {#s16}
------------

The study did not observe any major adverse events. Patients in the active and sham groups reported pricking \[9 (30.0%) vs 5 (16.7%)\], itchiness \[4 (13.3%) vs 3 (10.0%)\], and burning sensation \[2 (6.7%) vs 2 (6.7%)\] under the electrodes and daytime sedation \[1 (3.3%) vs 1 (3.3%)\].

Discussion {#s17}
==========

To our knowledge, this is the largest randomized controlled trial thus far examining the therapeutic effects of fronto-temporal tDCS on AVHs in schizophrenia. The pilot study by [@CIT0009] demonstrated therapeutic effects of fronto-temporal tDCS on AVHs severity in schizophrenia. Fronto-temporal tDCS was also expected to improve negative symptoms and depression symptoms through anodal tDCS acting on left dorsolateral prefrontal cortex (DLPFC) to increase its cortical excitability and thereby correct its hypoactivity on the premise that both negative symptoms ([@CIT0040]) and depression ([@CIT0023]) have been linked to hypofrontality. However, we did not find any significant effects of tDCS on AVHs severity in the primary outcome measure and other schizophrenia symptoms in the secondary outcome measures. Our negative results provide an observation that the tDCS treatment for medication-refractory AVHs is not as effective as previously reported. Our study has quite strong statistical power for the primary outcome. Thus, a false-negative result due to type II statistical error coming from insufficient statistical power is presently unlikely. In fact, the clinical value of fronto-temporal tDCS for treating AVHs in schizophrenia is being called into question ([@CIT0039]). Evidence in magnet treatment for AVHs in schizophrenia also suggests a similar scenario, in which transcranial magnetic stimulation directed at the left temporo-parietal area showed promising impact on AVHs symptoms in earlier trials, but effect sizes of this modality have a tendency to decrease over time along with publication of larger trials ([@CIT0047]; [@CIT0027]).

On the other hand, our negative results on the effects of tDCS on other schizophrenia symptoms are also unlikely to be false-negative because the statistical power for the secondary outcomes is equally strong as that for the primary outcome. On the contrary, the positive results of tDCS reducing negative and depression symptoms reported in the pilot study were at increased risk for change findings or false-positive errors because the power of statistical tests for the secondary outcomes was greatly reduced (a power of 0.826 and 0.561 for independent *t* test and for RMANOVA, respectively, to detect a small effect) and Bonferroni correction was not used neither. In line with our study, several other studies reported no significant effects of fronto-temporal tDCS on schizophrenia symptoms as measured by the PANSS ([@CIT0017]; [@CIT0048]).

Several possible reasons might have contributed to our negative results. For one, we did not take into account the possibility that the receptor binding profiles of antipsychotics taken by the patients may impact the treatment effects of tDCS. Recent research indicated antipsychotic drug type (as defined by high vs low dopamine D2 receptor affinity) may influence the therapeutic effects of add-on tDCS on AVHs in schizophrenia ([@CIT0001]). It may help clarify the issue by comparing the drug type of concomitant use of antipsychotics in our study with that in previous studies showing positive findings. Another possible reason was our heterogeneous sample comprising patients with schizophrenia and schizoaffective disorder. Some patients in our study had a wide range of symptom profiles, that is, a complex mixture of delusions, disorganized speech and behaviors, negative symptoms, depression, and AVHs. Now that fronto-temporal tDCS was scheduled to target the specific symptoms of AVHs, its therapeutic effects on AVHs might be obscured if the investigation was carried on the patient population with mixed symptoms.

The present study used conventional tDCS, which stimulates cortical areas via large sponge electrodes and with low precision spatial localization. A growing body of research suggests the use of high definition tDCS, which targets cortical areas using arrays of electrodes on the scalp and thereby focalizes the delivery of electrical current to the discrete brain regions ([@CIT0006]) and emphasizes the value of electroencephalography-based approach in guiding stimulation, individualizing, and optimizing tDCS protocols ([@CIT0015]; [@CIT0049]). The effects of tDCS on AVHs in schizophrenia should be validated by future studies using the combination of these new tools.

Research has indicated that precise identification of potential responders for the noninvasive brain stimulation is a key to success in AVHs treatment ([@CIT0027]). Of note, the average daily chlorpromazine equivalent dose given in our patient population is much less than that reported in the pilot study. A possible reason for our negative results is that patients with refractory AVHs may be candidate responders particularly benefiting from the prevailing stimulation protocol of fronto-temporal tDCS if they could tolerate higher dosage of antipsychotic medications. For those who are unable to tolerate high-dose antipsychotics, further studies should verify whether a more intensive stimulation protocol can improve the success rate of tDCS without jeopardizing their safety, for example, 3 times daily for 5 days (15 sessions).

In secondary outcome analyses, fronto-temporal tDCS led to improvement in insight into illness and positive symptoms. Our study is the first and largest randomized controlled trial to approve the beneficial effects of tDCS on impaired insight in schizophrenia. The positive results are unlikely due to chance alone given that the strong statistical power along with corrections for the multiple comparisons have protected these secondary outcome measures against the risk of type I error and thus have other underlying causes for their occurrence.

Insight of schizophrenia patients is a multidimensional concept that includes elements of different domains of awareness and ability to attribute symptoms to mental illness ([@CIT0003]). In the interhemispheric imbalance theory of impaired insight in schizophrenia, insight deficits are thought to stem from left dominant brain hemisphere activity ([@CIT0045]). The theory has gained the support of recent functional imaging research that attributes impaired insight to aberrant functional connectivity in neural networks of left hemisphere ([@CIT0021]) and suggests several left-hemispheric regions representing putative targets for noninvasive neuromodulation treatment to intensify insight in schizophrenia ([@CIT0022]). In addition, evidence has suggested that unawareness of symptoms in schizophrenia is associated with anatomical deficits in prefrontal cortex ([@CIT0037]) as well as increased activations in this brain region, which may be a compensatory mechanism of prefrontal impairment ([@CIT0043]). It has also been suggested that unawareness of illness correlates with anatomical deficits ([@CIT0005]) and compensatory hyperactivity ([@CIT0041]) of prefrontal cortex, particularly in the left hemisphere ([@CIT0010]; [@CIT0022]). One might intuitively wonder that our positive effects of tDCS on insight are a result of the anodal tDCS acting on left prefrontal cortex to augment the endogenous effort to compensate for prefrontal deficits. However, previous research indicated the linkage between unawareness of symptoms and white matter disruption in fronto-temporal brain regions ([@CIT0004]). More recent research provided further evidence for the ability of tDCS to modify white matter connectivity ([@CIT0030]) and in particular fronto-temporal tDCS to increase the resting-state functional connectivity between the left TPJ and the left DLPFC in schizophrenia patients ([@CIT0034]). Thus, the fronto-temporal montage used in the present study is also a possible factor contributing to the positive effects on insight into positive symptoms.

In our study, the effect of tDCS on insight into negative symptoms is not as evident as that for insight into positive symptoms. Contrary to the interhemispheric imbalance theory of impaired insight in schizophrenia, some researchers reported that illness unawareness and symptoms unawareness were associated with reduced gray matter volume in right-hemispheric fronto-temporo-parietal brain regions ([@CIT0020]) and DLPFC ([@CIT0044]), respectively. Future studies are needed to examine if bilateral bicephalic tDCS ([@CIT0026]) with fronto-temporal montage placement could improve insight into both positive and negative symptoms. Notwithstanding some promising results on insight enhancement, it should be noted that these positive findings need to be taken with great caution because volunteer bias, a subtype of selection bias, likely occurred in our study in which psychotic patients who volunteered for such an interventional trial already had a certain awareness of their own situations and thus may not be a full representative of the whole population.

It is clear that the completion rate of our clinical trial was high and fronto-temporal tDCS was well tolerated in our participants. No significant adverse events were observed, and patients in both active and sham groups reported no significant difference in mild side effects of stimulation. All these findings further strengthen the safety profile of tDCS in schizophrenia patients ([@CIT0039]) and approve tDCS and sham stimulation for double-blind, sham-controlled study designs ([@CIT0019]).

Our study has several limitations. First, the abbreviated version of the SUMD has better acceptability in clinical practices but narrower definition of insight than the longer version does. Lack of assessment of attribution dimension in this short-form scale limits the interpretations of our results. Second, the interpretation of tDCS-associated positive effects on insight in schizophrenia is highly speculative because our study lacks the support from functional neuroanatomical or electrophysiological evidence. The underlying mechanism of our observations should be confirmed in future research with simultaneous electroencephalography recording during tDCS in these patients. Finally, there is debate about the role of insight in the treatment of schizophrenia. Interventions to promote insight in schizophrenia have been viewed by some researchers as a double-edged sword because heightened insight has been linked not only to better clinical outcomes, but also to worse psychological outcomes (depression, low self-esteem, increased levels of self-stigma, and suicidality) ([@CIT0051]; [@CIT0012]). Researchers applying noninvasive neuromodulation treatment in an attempt to heighten insight of schizophrenia patients should monitor the risk factors so as to maximize the beneficial effects of treatment-associated insight enhancement.

CONCLUSION {#s18}
==========

In summary, we observed no therapeutic effects of fronto-temporal tDCS on AVHs and other schizophrenia symptoms. Further studies should focus on more intensive and individualized protocols and the use of more focalized stimulation device to maximize the efficacy of fronto-temporal tDCS for these symptoms. Further, our results suggest that add-on tDCS in schizophrenia patients is an effective and safe intervention to facilitate patients' insight into illness and symptoms. The promising results should be confirmed in future replication studies.
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